Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

HANOI, VIETNAM – Media OutReach Neswire – 14 April 2025 – Together with world-renowned scientists including Prof. Joel F.

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide ... specifically a heart failure urgent visit or hospitalisation, oral diuretic ...

HANOI, VIETNAM - Media OutReach Neswire - 14 April 2025 - Together with world-renowned scientists including Prof. Joel F.

Prof. Daniel Drucker’s pioneering work on GLP-1, in collaboration with world-renowned scientists, has transformed treatment for diabetes and obesity - and is now opening new frontiers in ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

“Patients with heart valve issues should be particularly cautious about any oral care tools that could introduce bacteria into the bloodstream.” These tools pose similar risks to people with ...